To explore the relationship between the triglyceride-glucose (TyG) index and the severity and short-term outcomes in patients with Guillain-Barré syndrome (GBS), highlighting its potential significance as a biomarker.
Key Findings:
The TyG index is an independent risk factor for severe GBS (OR: 2.77; 95% CI: [1.51-5.30]; P = 0.001).
Albumin and MRC sum score are protective factors against severe GBS.
The TyG index is also an independent risk factor for poor short-term prognosis (OR: 1.85; 95% CI: [1.05-3.32]; P = 0.036).
The TyG index showed a linear correlation with severe GBS and short-term poor prognosis.
Combined with clinical markers, the TyG index improved predictive accuracy for severe GBS and poor prognosis.
Interpretation:
Elevated TyG index is linked to increased risks of severe GBS and poor short-term outcomes, suggesting its potential role in risk stratification and clinical decision-making.
Limitations:
The study is retrospective and may be subject to selection bias.
The sample size may limit the generalizability of the findings, and potential confounding factors should be considered.
Conclusion:
The TyG index may serve as a useful biomarker for predicting severity and short-term outcomes in GBS patients, emphasizing its importance in clinical practice.
Autopsy-confirmed findings linked diagnostic errors, co-pathology, and genetic variation to distinct pathologic patterns across more than 3,300 donors with Parkinsonian disorders.
